Table 2. Characteristics of LVAD recipients with and without false positive hepatitis C serology.
| Clinical characteristics | False positive | True negative | P |
|---|---|---|---|
| Gender | 0.086 | ||
| Male | 10 | 21 | |
| Female | 0 | 8 | |
| Mean age at LVAD implantation (years) | 64.3±5.9 | 50.3±14.9 | <0.001 |
| Mean duration LVAD to heart transplantation (days) | 239.2±242.8 | 283.8±172.2 | 0.5297 |
| Mean interval from LVAD implantation to FPHC (days) | 163.4±73.9 | NA | |
| Number of RBC transfusions | 16.1±17.48 | 7.55±7.11 | 0.0344 |
| Number of FFP transfusions | 3.7±3.37 | 2.45±2.8 | 0.2498 |
| cPRA class I (%) | 22±37 | 23±31 | 0.9443 |
| cPRA class II (%) | 40±50 | 25±34 | 0.3776 |
LVAD, left ventricular assist device; FPHC, false positive hepatitis C test; NA, not applicable; RBC, red blood cell; FFP, fresh frozen plasma; cPRA, calculated panel reactive anti-HLA antibody.